These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 34739225)

  • 1. Targeting Cancer Chemotherapy Resistance by Precision Medicine-Driven Nanoparticle-Formulated Cisplatin.
    Siemer S; Bauer TA; Scholz P; Breder C; Fenaroli F; Harms G; Dietrich D; Dietrich J; Rosenauer C; Barz M; Becker S; Strieth S; Reinhardt C; Fauth T; Hagemann J; Stauber RH
    ACS Nano; 2021 Nov; 15(11):18541-18556. PubMed ID: 34739225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of LRRC8A protects human ovarian and alveolar carcinoma cells against Cisplatin-induced expression of p53, MDM2, p21Waf1/Cip1, and Caspase-9/-3 activation.
    Sørensen BH; Nielsen D; Thorsteinsdottir UA; Hoffmann EK; Lambert IH
    Am J Physiol Cell Physiol; 2016 Jun; 310(11):C857-73. PubMed ID: 26984736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual role of LRRC8A-containing transporters on cisplatin resistance in human ovarian cancer cells.
    Sørensen BH; Dam CS; Stürup S; Lambert IH
    J Inorg Biochem; 2016 Jul; 160():287-95. PubMed ID: 27112899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquired cisplatin resistance in human ovarian A2780 cancer cells correlates with shift in taurine homeostasis and ability to volume regulate.
    Sørensen BH; Thorsteinsdottir UA; Lambert IH
    Am J Physiol Cell Physiol; 2014 Dec; 307(12):C1071-80. PubMed ID: 25252947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of the volume-regulated anion channel components LRRC8A and LRRC8D limits platinum drug efficacy.
    Widmer CA; Klebic I; Domanitskaya N; Decollogny M; Howald D; Siffert M; Essers P; Nowicka Z; Stokar-Regenscheit N; van de Ven M; de Korte-Grimmerink R; Galván JA; Pritchard CEJ; Huijbers IJ; Fendler W; Vens C; Rottenberg S
    Cancer Res Commun; 2022 Oct; 2(10):1266-1281. PubMed ID: 36467895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Profiling Cisplatin Resistance in Head and Neck Cancer: A Critical Role of the VRAC Ion Channel for Chemoresistance.
    Siemer S; Fauth T; Scholz P; Al-Zamel Y; Khamis A; Gül D; Freudelsperger L; Wollenberg B; Becker S; Stauber RH; Hagemann J
    Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanoscale drug delivery platforms overcome platinum-based resistance in cancer cells due to abnormal membrane protein trafficking.
    Xue X; Hall MD; Zhang Q; Wang PC; Gottesman MM; Liang XJ
    ACS Nano; 2013 Dec; 7(12):10452-64. PubMed ID: 24219825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisense LNA-loaded nanoparticles of star-shaped glucose-core PCL-PEG copolymer for enhanced inhibition of oncomiR-214 and nucleolin-mediated therapy of cisplatin-resistant ovarian cancer cells.
    Vandghanooni S; Eskandani M; Barar J; Omidi Y
    Int J Pharm; 2020 Jan; 573():118729. PubMed ID: 31705975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple-combination therapy assisted with ultrasound-active gold nanoparticles and ultrasound therapy against 3D cisplatin-resistant ovarian cancer model.
    Kip B; Tunc CU; Aydin O
    Ultrason Sonochem; 2022 Jan; 82():105903. PubMed ID: 34974392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Precisely Assembled Nanoparticles against Cisplatin Resistance via Cancer-Specific Targeting of Mitochondria and Imaging-Guided Chemo-Photothermal Therapy.
    Yang GG; Pan ZY; Zhang DY; Cao Q; Ji LN; Mao ZW
    ACS Appl Mater Interfaces; 2020 Sep; 12(39):43444-43455. PubMed ID: 32883070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanotechnology-Based Cisplatin Intracellular Delivery to Enhance Chemo-Sensitivity of Ovarian Cancer.
    Bortot B; Mongiat M; Valencic E; Dal Monego S; Licastro D; Crosera M; Adami G; Rampazzo E; Ricci G; Romano F; Severini GM; Biffi S
    Int J Nanomedicine; 2020; 15():4793-4810. PubMed ID: 32764921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug.
    Xu X; Xie K; Zhang XQ; Pridgen EM; Park GY; Cui DS; Shi J; Wu J; Kantoff PW; Lippard SJ; Langer R; Walker GC; Farokhzad OC
    Proc Natl Acad Sci U S A; 2013 Nov; 110(46):18638-43. PubMed ID: 24167294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rational design of polyion complex nanoparticles to overcome cisplatin resistance in cancer therapy.
    Yang XZ; Du XJ; Liu Y; Zhu YH; Liu YZ; Li YP; Wang J
    Adv Mater; 2014 Feb; 26(6):931-6. PubMed ID: 24338636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.
    Holloway RW; Mehta RS; Finkler NJ; Li KT; McLaren CE; Parker RJ; Fruehauf JP
    Gynecol Oncol; 2002 Oct; 87(1):8-16. PubMed ID: 12468336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Whole-genome CRISPR Screen Identifies a Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer.
    Goodspeed A; Jean A; Costello JC
    Eur Urol; 2019 Feb; 75(2):242-250. PubMed ID: 30414698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subunit composition of VRAC channels determines substrate specificity and cellular resistance to Pt-based anti-cancer drugs.
    Planells-Cases R; Lutter D; Guyader C; Gerhards NM; Ullrich F; Elger DA; Kucukosmanoglu A; Xu G; Voss FK; Reincke SM; Stauber T; Blomen VA; Vis DJ; Wessels LF; Brummelkamp TR; Borst P; Rottenberg S; Jentsch TJ
    EMBO J; 2015 Dec; 34(24):2993-3008. PubMed ID: 26530471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multipronged Design of Light-Triggered Nanoparticles To Overcome Cisplatin Resistance for Efficient Ablation of Resistant Tumor.
    Li Y; Deng Y; Tian X; Ke H; Guo M; Zhu A; Yang T; Guo Z; Ge Z; Yang X; Chen H
    ACS Nano; 2015 Oct; 9(10):9626-37. PubMed ID: 26365698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
    Bar-Zeev M; Livney YD; Assaraf YG
    Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biocompatible AIEgen/p-glycoprotein siRNA@reduction-sensitive paclitaxel polymeric prodrug nanoparticles for overcoming chemotherapy resistance in ovarian cancer.
    Wu J; Wang Q; Dong X; Xu M; Yang J; Yi X; Chen B; Dong X; Wang Y; Lou X; Xia F; Wang S; Dai J
    Theranostics; 2021; 11(8):3710-3724. PubMed ID: 33664857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MTDH/AEG-1 downregulation using pristimerin-loaded nanoparticles inhibits Fanconi anemia proteins and increases sensitivity to platinum-based chemotherapy.
    Bi J; Areecheewakul S; Li Y; Yang S; Zhang Y; Ebeid K; Li L; Thiel KW; Zhang J; Dai D; Salem AK; Leslie KK; Meng X
    Gynecol Oncol; 2019 Nov; 155(2):349-358. PubMed ID: 31477281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.